A carregar...
Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effects that impact on quality of life. A major advance...
Na minha lista:
| Publicado no: | Case Rep Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7125505/ https://ncbi.nlm.nih.gov/pubmed/32274226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/9571691 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|